|
| |
| | Geneva v. GLAXOSMITHKLINE PLC |
 | | GlaxoSmithKline, PLC, SmithKline Beecham Corporation, SmithKline Beecham PLC, and Beecham Group PLC (collectively GSK) own the 1985 and 2000/01 patents, which relate to the antibiotic clavulanic acid and its salts. | | | SMITHKLINE BEECHAM CORPORATION (doing business as GlaxoSmithKline Inc.), | | | SMITHKLINE BEECHAM CORPORATION (doing business as GlaxoSmithKline Inc.), SMITHKLINE BEECHAM PLC, and BEECHAM GROUP PLC, |
|
http://www.ll.georgetown.edu/federal/judicial/fed/opinions/02opinions/02-1439.html
(5777 words)
|
|
| |
| | GlaxoSmithKline Australia - 11 Sep 2000 - Glaxo Wellcome and SmithKline Beecham Merger Update |
| | The directors of Glaxo Wellcome and the directors of SmithKline Beecham jointly accept responsibility for the information contained in this announcement other than the information relating solely to Glaxo Wellcome and SmithKline Beecham and their respective subsidiaries, associates, shareholders and directors, for which the directors of Glaxo Wellcome and SmithKline Beecham respectively accept such responsibility. | | | Glaxo Wellcome and SmithKline Beecham today announce that, while progress continues to be made in their planned merger to form GlaxoSmithKline, the completion date will be delayed until after the previously announced date of 25th September. | | | To the best of the knowledge, information and belief of such directors (who have taken all reasonable care to ensure that such is the case), the information contained in this announcement for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information. |
|
http://www.gsk.com.au/gskinternet/publishing.nsf/Content/12Jul2002-MergerUpdate
(5777 words)
|
|
| |
| | (WO 01/09350) GENETICALLY ENGINEERED BLEB VACCINE [Repub: 30.08.2001] |
| | LOBET, Yves [BE/BE]; SmithKline Beecham Biologicals s.a., 89, rue de l'Institut, B-1330 Rixensart (BE). | | | DENOEL, Philippe [BE/BE]; SmithKline Beecham Biologicals s.a., 89, rue de l'Institut, B-1330 Rixensart (BE). | | | THIRY, Georges [BE/BE]; SmithKline Beecham Biologicals s.a., 89, rue de l'Institut, B-1330 Rixensart (BE). |
|
http://www.wipo.int/ipdl/IPDL-CIMAGES/view/pct/getbykey5?KEY=01/09350.010830
(289 words)
|
|
| |
| | (WO 00/07024) METHOD OF PROTEIN ANALYSIS [Repub: 11.05.2000] |
| | YALLOP, Rhiannon [GB/GB]; SmithKline Beecham Pharmaceuticals, The Frythe, Welwyn, Hertfordshire AL6 9AR (GB). | | | WILDSMITH, Sophie, Elizabeth, Victoria [GB/GB]; SmithKline Beecham Pharmaceuticals, The Frythe, Welwyn, Hertfordshire AL6 9AR (GB). | | | BUGELSKI, Peter, John [US/GB]; SmithKline Beecham Pharmaceuticals, The Frythe, Welwyn, Hertfordshire AL6 9AR (GB). |
|
http://www.wipo.int/ipdl/IPDL-CIMAGES/view/pct/getbykey5?KEY=00/07024.000511
(289 words)
|
|
| |
| | Merger of SmithKline Beecham And Glaxo Wellcome |
| | The Federal Trade Commission today accepted a proposed consent order that would allow the merger of pharmaceutical manufacturers SmithKline Beecham plc ("SB") and Glaxo Wellcome plc ("Glaxo"), while addressing a range of competitive concerns that would have resulted from the transaction as originally proposed. | | | In the Matter of Glaxo Wellcome plc, and SmithKline Beecham plc. | | | Resolving Competitive Concerns, FTC Agreement Clears $182 Billion Merger of SmithKline Beecham and Glaxo Wellcome |
|
http://www.ftc.gov/opa/2000/12/skb.htm
(2297 words)
|
|
| |
| | domain-B : Indian business : companies : SmithKline Beecham to launch anti-diabetic drug |
| | SmithKline Beecham Pharma India Ltd, the Rs 300-crore subsidiary of the Anglo-US pharma multinational, has applied for an Indian drug registration to introduce its newly developed anti-diabetic drug Avandia. | | | Daniel McDonald, managing director, SmithKline Beecham Pharma, says the drug is a therapeutic breakthrough with the potential to generate $2-3 billion in global sales within the next three years. | | | SmithKline Beecham Pharma India has firmed up plans to produce the anti-diabetic drug locally at its bulk drug and formulation facility in Mysore. |
|
http://www.domainb.com/companies/companies_s/skbpharma_india/19990710skbpharma_india.html
(339 words)
|
|
| |
| | KANYARÓ, MUMPSZ, RUBEOLA ELLENI VÉDÕOLTÁS |
| | Védõoltásra hazánkban az alábbi monovalens készítmények is rendelkezésre állanak, illetve beszerezhetõk (kanyaró: Rimevaxâ, SmithKline Beecham; Attenuvaxâ, Merck Sharp Dohme; rubeola: Ervevaxâ, SmithKline Beecham; MeruVaxâ, Merck Sharp Dohme; mumpsz: Pariorixâ, SmithKline Beecham, MumpsVaxâ, Merck Sharp Dohme, stb.). | | | Thrombocytopenia mind a morbilli, mind a rubeola komponens hatására kialakulhat, ritkán szorul kezelésre, ha igen, steroid adandó. | | | A rubeola elleni aktív immunizálás is élõ, attenuált rubeolavírussal történik, az inaktivált vírusvakcinációk itt sem váltak be. |
|
http://www.c3.hu/~oltinfo/betmmr.htm
(339 words)
|
|
| |
| | Vaccines |
| | PEDIARIX™-Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined-Manufactured by SmithKline Beecham Biologicals Rixensart, Belgium, and Chiron Behring GmbH and Co Marburg, Germany, | | | PEDIARIX™-Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined-Manufactured by SmithKline Beecham Biologicals Rixensart, Belgium, and Chiron Behring GmbH and Co Marburg, Germany, Distributed by SmithKline Beecham Pharmaceuticals, Philadelphia, PA 19101 | | | INFANRIX®-Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed-Manufactured by GlaxoSmithKline Biologicals Rixensart, Belgium, and Chiron Behring GmbH and Co Marburg, Germany, Distributed by GlaxoSmithKline Research Triangle Park, NC 27709 |
|
http://users.adelphia.net/~cdc/Vaccines.htm
(2346 words)
|
|
| |
| | Geneva v. GLAXOSMITHKLINE PLC |
| | SMITHKLINE BEECHAM CORPORATION (doing business as GlaxoSmithKline Inc.), SMITHKLINE BEECHAM PLC, and BEECHAM GROUP PLC, | | | Dimitrios T. Drivas, White and Case, of New York, New York, argued for plaintiff-counterclaim defendants-appellees Geneva Pharmaceuticals, Inc. Of counsel was Leslie Morioka. |
|
http://www.ll.georgetown.edu/federal/judicial/fed/opinions/02opinions/02-1439.html
(2346 words)
|
|
| |
| | U.S.-Cuba Trade and Economic Council, Inc./Economic Eye on Cuba© |
| | SmithKline Beacham currently markets vaccines to prevent Meningitis A and to prevent Meningitis C. The Finlay Institute could eventually receive US$10 million to US$20 million from SmithKline Beecham plc for a five-year exclusive right to market the vaccine. | | | If the Meningitis B vaccine is marketed, SmithKline Beacham will then make royalty payments to Carlos Finlay Institute in U.S. Dollars or their equivalent. | | | Under the terms of the OFAC license, during the testing and clinical trial stages, SmithKline Beacham will compensate Carlos Finlay Institute in the form of products (perhaps healthcare products and food products) equal to the U.S. Dollar value of the compensation. |
|
http://www.cubatrade.org/eyeonz35.html
(1606 words)
|
|
| |
| | Quantitative Assessment of Aortic Atherosclerosis in APOE*3 Leiden Transgenic Mice and Its Relationship to Serum Cholesterol Exposure -- Groot et al. 16 (8): 926 -- Arteriosclerosis, Thrombosis, and Vascular Biology |
| | the Department of Vascular Biology, SmithKline Beecham Pharmaceuticals, The Frythe, Welwyn, Hertfordshire, UK (P.H.E.G., G.M.B., R.S., M.V.-H.), and TNO-Prevention and Health, Gaubius Laboratory, Leiden, The Netherlands (B.J.M. van V., M.H.H., L.M.H). | | | Correspondence to Pieter H.E. Groot, SmithKline Beecham Pharmaceuticals, The Frythe, Welwyn (Herts), AL6 9AR, UK. | | | E variant, APOE*3 Leiden, develop hyperlipidemia and are highly |
|
http://atvb.ahajournals.org/cgi/content/full/16/8/926
(1606 words)
|
|
| |
| | Effects of the Glucocorticoid II Receptor Antagonist Mifepristone on Hypertension in the Obese Zucker Rat -- Clapham and Turner 282 (3): 1503 -- Journal of Pharmacology And Experimental Therapeutics |
| | Department of Vascular Biology, SmithKline Beecham Pharmaceuticals, The Frythe, Welwyn, Hertfordshire AL6 9AR, U.K. Abstract | | | Send reprint requests to: Dr. John C. Clapham, Department of Vascular Biology, SmithKline Beecham Pharmaceuticals, The Frythe, Welwyn, Hertfordshire AL6 9AR, U.K. Abbreviations | | | We have investigated the possible involvement of endogenous corticosteroids in the maintenance of hypertension in aged lean |
|
http://www.jpet.org/cgi/content/full/282/3/1503
(1606 words)
|
|
| |
| | GlaxoSmithKline - Share capital |
| | Prior to the merger between Glaxo Wellcome and SmithKline Beecham on 27th December 2000, several shareholders had an interest of more than three per cent in the share capital of Glaxo Wellcome or SmithKline Beecham (excluding The Bank of New York as depositary for the ADRs of each company). | | | Updated March 22, 2001 - © 2001 GlaxoSmithKline - All Rights Reserved | | | As far as is known to the company, no other person was the owner of more than three per cent of the Ordinary Shares of the company. |
|
http://www.gsk.com/financial/reports/ar/report/share_cap/share_cap.html
(542 words)
|
|
| |
| | SmithKline Beecham Enters Into Advanced Technology Access Program With LJL BioSystems |
| | Prior to release of FLARe system to the general market, LJL plans to work with select collaborators, such as SmithKline Beecham, who have comparable technical expertise, immediate need for this leading edge technology, and the ability to fund development. | | | SmithKline Beecham Enters Into Advanced Technology Access Program With LJL BioSystems | | | LJL's proprietary technology platform is designed to address many of the limitations associated with current products for the HTS market, allowing its customers to expedite the identification and optimization of compounds for development into new medicines. |
|
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-09-1998/0000746947&EDATE=
(438 words)
|
|
| |
| | SmithKline Beecham's Timentin(R) Is Cleared for Use in Pediatric Patients |
| | SmithKline Beecham's Timentin(R) Is Cleared for Use in Pediatric Patients | | | PHILADELPHIA, Jan. 12 /PRNewswire/ -- SmithKline Beecham's Timentin(R) (ticarcillin disodium/clavulanate potassium), until now an injectable antibiotic reserved for use in adult patients, has been cleared by the U.S. Food and Drug Administration for use in treating a wide range of infections in children age 3 months to 16 years, the company announced today. | | | Timentin, composed in part of the beta-lactam antibiotic ticarcillin, is expressly designed to overcome a mechanism by which several important bacterial pathogens become resistant to therapy. |
|
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/1-12-98/392007&EDATE=
(314 words)
|
|
| |
| | A Suicide Side Effect? / What parents aren't being told about their kids' antidepressants |
| | Because Paxil and Zoloft were members of the same chemical class as Prozac, the FDA asked officials at SmithKline Beecham (the predecessor to GlaxoSmithKline) and Pfizer, Zoloft's maker, to submit reviews on the drugs' effect on suicidal behavior of patients. | | | Brecher called Thomas Donnelly, a SmithKline Beecham executive, and asked him to prepare such a report. | | | One side effect of SSRIs, recognized for at least 15 years, is a sensation called akathisia, a restless agitation that ranges from jitteriness to a sensation described by some people as "jumping out of their skin." Healy believes akathisia is the principal trigger for impulsive violence in some people taking SSRIs. |
|
http://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2004/01/04/CM118608.DTL
(5201 words)
|
|
| |
| | Intellectual Property Newsletter - London - January 2003 |
| | In the case of Synthon BV v SmithKline Beecham plc, Synthon sought to revoke SmithKline Beechams (SKB) UK patent for a paroxetine salt used in the treatment of depression and Parkinsons disease, on the grounds that it was not new. | | | Synthon had filed an earlier patent application which disclosed a method of making the salt and the product itself although the description of the salt in Synthons application was different to that in SKBs patent. | | | Jacob J held that it was Synthon who first invented the paroxetine salt, including the crystal form which was at the heart of SKBs patent. |
|
http://www.bakernet.com/newsletters/Newsletter_Full.asp?NLID=8&EditionID=118
(5201 words)
|
|
| |
| | Dr David Healy |
| | He was employed by SmithKline Beecham in the 1980s as a clinical trialist for paroxetine (Paxil / Seroxat) which they'd bought from Ferrosan in 1978. | | | Later in 2001, Healy was asked to uncover documents buried by Smithkline Beecham in the case of Donald Schell, who killed his wife, daughter and granddaughter after 2 days on Paxil. | | | Despite this ruling, and despite the MHRA having had the information for 10 years, doctors and psychiatrists were still overprescribing Paxil/Seroxat, which is responsible for up to 19,000 deaths in the US. |
|
http://www.deep-trance.com/treatment/dr-david-healy.html
(224 words)
|
|
| |
| | Dr David Healy |
| | Later in 2001, Healy was asked to uncover documents buried by Smithkline Beecham in the case of Donald Schell, who killed his wife, daughter and granddaughter after 2 days on Paxil. | | | He was employed by SmithKline Beecham in the 1980s as a clinical trialist for paroxetine (Paxil / Seroxat) which they'd bought from Ferrosan in 1978. | | | Dr David Healy found himself at the heart of the overmedicating debate. |
|
http://www.deep-trance.com/treatment/dr-david-healy.html
(209 words)
|
|
| |
| | Reconcilliation to US accounting principles |
| | As the combination of Glaxo Wellcome and SmithKline Beecham is accounted for as a merger under UK GAAP, the financial statements of GlaxoSmithKline under UK GAAP represent the combined financial statements of Glaxo Wellcome and SmithKline Beecham on a historical basis for all periods presented. | | | Under US GAAP, this business combination did not qualify for pooling of interests accounting and Glaxo Wellcome was determined to be the accounting acquirer in a purchase acquisition dated 27th December 2000. | | | Fair value adjustments to the recorded amount of inventory will be expensed in the period the inventory will be utilised and additional amortisation and depreciation will be recorded in respect of the fair value adjustments to tangible and intangible assets and the resulting goodwill over the periods of their respective economic useful lives. |
|
http://www.gsk.com/financial/reports/ar/report/notes_to_finstat/recon_us_acc_princ/recon_us_acc_princ.html
(1810 words)
|
|
| |
| | Journal of Cerebral Blood Flow & Metabolism - Abstract of article: The Effects of SB 206284A, A Novel Neuronal Calcium-Channel Antagonist, in Models of Cerebral Ischemia |
| | SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, U.S.A. Correspondence: Tom C Hamilton, Department of Neurosciences, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW United Kingdom. | | | Wood is currently at Herchel Smith Laboratory for Medicinal Chemistry, School of Clinical Medicine, University of Cambridge, United Kingdom. | | | , Nicole A Samson, Susan J Smith and A Jackie Hunter |
|
http://www.nature.com/jcbfm/journal/v17/n4/abs/9590218a.html
(1810 words)
|
|
| |
| | Final Technical Session Program |
| | (1) Cheminformatics Department, SmithKline Beecham Pharmaceuticals, 709 Swedeland Road, King of Prussia, PA 19406, Stephen_2_Johnson@sbphrd.com, (2) Physical and Structural Chemistry, SmithKline Beecham Pharmaceuticals | | | Other considerations are whether a library substance has been added to the CAS Registry, appeared in a patent, or has a commercially-available synthetic precursor, etc. This paper will discuss screening results for some example substance sets. | | | In the last several years, consideration of the oral bioavailability of drugs has assumed greater importance in the early discovery phase of pharmaceutical research. |
|
http://www.lib.uchicago.edu/cinf/220nm/final_program_220.html
(1810 words)
|
|
| |
| | wellcome.html |
| | The proposed merger between Glaxo Wellcome and Smithkline Beecham will create the worlds largest drugs group, which is to have its headquarters in New York. | | | Now, Glaxo Wellcome is to merge with Smithkline Beecham. | | | Henry Solomon Wellcome was born in poverty on 21 August, 1853, at Almond, Wisconsin, the son of the Reverend S. Wellcome, farmer and Adventist minister, and Mary Curtis Wellcome. |
|
http://www.pharmj.com/Editorial/20001223/articles/wellcome.html
(1196 words)
|
|
| |
| | RACGP Tetanus Vaccines |
| | Infanrix (diphtheria-tetanus-acellular pertussis adsorbed) -SmithKline Beecham (diphtheria toxoid >25 Lf, tetanus toxoid 10 Lf, pertussis toxoid 25µg, pertussis filamentous haemagglutinin 25µg, pertactin 8µg; adsorbed on to aluminium hydroxide; phenoxyethanol as preservative; 0.5 mL dose). | | | Infanrix-hepB (diphtheria-tetanus-acellular pertussis adsorbed-hepatitis B) - SmithKline Beecham (diphtheria toxoid 25 Lf, tetanus toxoid 10 Lf, pertussis toxoid 25µg, pertussis filamentous haemagglutinin 25µg, pertactin 8µg, hepatitis B surface antigen 10µg; adsorbed to aluminium hydroxide 0.5 mg, aluminium phosphate 0.2 mg, polysorbate 80 | | | Tripacel (diphtheria-tetanus-acellular pertussis adsorbed) -CSL/ Pasteur Merieux Connaught (diphtheria toxoid LFL equal or > 30 IU, tetanus toxoid LFL equal or > 40IU, pertussis toxoid 10µg, pertussis filamentous haemagglutinin 5µg, pertussis fimbriae 2+3 5µg, pertactin 3µg; 1.5µg aluminium phosphate as an adjuvant, and 3.4µg phenoxyethanol as a preservative; 0.5 mL dose). |
|
http://www.racgp.org.au/document.asp?id=1878
(1196 words)
|
|
| |
| | SmithKline Beecham and Paxil Petition |
| | The SmithKline Beecham and Paxil Petition to Smithkline Beecham was created by Individuals experiencing difficulty with the prescription drug paxil and written by k. | | | SKB boasts to the public in advertising that Paxil's "half life" is good for the patient, that a short half life specifically refines brain chemistry and reduces side effects--but they fail to tell the public that Paxil's half life is bad for the patient in terms of addiction and withdrawal problems. | | | SKB falsely advertises, through its Paxil labeling and otherwise, that only drug abusers are at risk of physical and psychological dependence, and withdrawal problems when tapering back or abruptly discontinuing Paxil usage. |
|
http://www.petitiononline.com/oky71
(250 words)
|
|
| |
| | Fool.com: Busy Week for Affymetrix [News] October 6, 2000 |
| | Affymetrix will be joined by Merck (NYSE: MRK), SmithKline Beecham (NYSE: SBH), the National Institutes of Health and one of the world's largest medical research charities, Wellcome Trust, in the effort. | | | This week, Affymetrix raised profit expectations for the balance of the year and also had pharmaceutical heavyweights Merck and SmithKline Beecham join its team that is aiming to sequence the mouse genome. | | | It's not surprising to see Affymetrix in favor of the freebie model since this information is a sort of "raw goods" for their biochips and research efforts. |
|
http://www.fool.com/news/2000/affx001006.htm
(250 words)
|
|
| |
| | C0A-202.HTML |
| | SmithKline Beecham, the producer of Panadol, recalled the drug and Panadeine which contains Panadol and Codeine. | | | Statement by Dr Tan Seng Giaw, DAP National Vice-Chairman and MP for Kepong on the recall of Panadol and Panadeine by SmithKline Beecham in Australia on 10 June 2000. | | | Further, the Health Ministry admits that it has conducted raids on backyard factories, making fake Panadol and other drugs. |
|
http://www.angelfire.com/journal2/tsgtan/POLITICAL/ARCHIVES/C0A-202.HTML
(250 words)
|
|
| |
| | King Pharmaceuticals Announces Appointment of Ted G. Wood to Board Of Directors |
| | Wood was President of Boehringer Mannheim Pharmaceutical Corporation in Rockville, Maryland from 1992 to 1993, and was employed by SmithKline Beecham Corporation from 1975 to 1991, where he served as President of Beecham Laboratories from 1988 to 1989 and Executive Vice President of SmithKline from 1990 to 1991. | | | Wood was President of KV Pharmaceuticals in St. Louis, Missouri from 1993 to 1994. | | | Ted G. Wood is the former President of The United Company in Bristol, Virginia, the position from which he retired in 2002. |
|
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/08-26-2003/0002006394&EDATE=
(418 words)
|
|
|
